JP2008501722A5 - - Google Patents

Download PDF

Info

Publication number
JP2008501722A5
JP2008501722A5 JP2007519572A JP2007519572A JP2008501722A5 JP 2008501722 A5 JP2008501722 A5 JP 2008501722A5 JP 2007519572 A JP2007519572 A JP 2007519572A JP 2007519572 A JP2007519572 A JP 2007519572A JP 2008501722 A5 JP2008501722 A5 JP 2008501722A5
Authority
JP
Japan
Prior art keywords
disease
disorder
pharmaceutical composition
composition according
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2007519572A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008501722A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CA2005/000891 external-priority patent/WO2005121095A1/en
Publication of JP2008501722A publication Critical patent/JP2008501722A/ja
Publication of JP2008501722A5 publication Critical patent/JP2008501722A5/ja
Pending legal-status Critical Current

Links

JP2007519572A 2004-06-10 2005-06-07 C5a拮抗剤としてのピリジン誘導体 Pending JP2008501722A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US57850004P 2004-06-10 2004-06-10
PCT/CA2005/000891 WO2005121095A1 (en) 2004-06-10 2005-06-07 Pyridine analogs as c5a antagonists

Publications (2)

Publication Number Publication Date
JP2008501722A JP2008501722A (ja) 2008-01-24
JP2008501722A5 true JP2008501722A5 (enExample) 2008-05-08

Family

ID=35502992

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007519572A Pending JP2008501722A (ja) 2004-06-10 2005-06-07 C5a拮抗剤としてのピリジン誘導体

Country Status (7)

Country Link
US (2) US7429666B2 (enExample)
EP (1) EP1758865A4 (enExample)
JP (1) JP2008501722A (enExample)
CN (1) CN1968931A (enExample)
AU (1) AU2005251839A1 (enExample)
CA (1) CA2568673A1 (enExample)
WO (1) WO2005121095A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7429666B2 (en) * 2004-06-10 2008-09-30 Merck Frosst Canada Ltd. Pyridine analogs as C5a antagonists
BRPI0708337A2 (pt) * 2006-02-28 2011-05-24 Helicon Therapeutics Inc pipirazinas terapêutica como inibidores pde4
US8927546B2 (en) 2006-02-28 2015-01-06 Dart Neuroscience (Cayman) Ltd. Therapeutic piperazines
WO2008009062A1 (en) * 2006-07-21 2008-01-24 Promics Pty Ltd Treatment for intimal hyperplasia and related conditions
AU2007305269A1 (en) * 2006-10-04 2008-04-10 Schering Corporation Bicyclic and tricyclic derivatives as thrombin receptor antagonists
CN103168031A (zh) * 2010-10-20 2013-06-19 霍夫曼-拉罗奇有限公司 作为ampk活化剂的四氢喹啉衍生物
US8846656B2 (en) 2011-07-22 2014-09-30 Novartis Ag Tetrahydropyrido-pyridine and tetrahydropyrido-pyrimidine compounds and use thereof as C5a receptor modulators
US9289467B2 (en) 2011-08-10 2016-03-22 Case Western Reserve University Compositions and methods for treating bone conditions
CN108508130B (zh) * 2018-04-11 2020-01-17 国家烟草质量监督检验中心 一种超高效合相色谱-串联质谱技术拆分、测定手性农药甲霜灵和烯酰吗啉对映体的方法
WO2022266368A1 (en) * 2021-06-16 2022-12-22 The Cleveland Clinic Foundation Protease inhibitors and methods of use

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002022556A1 (en) 2000-09-14 2002-03-21 Mitsubishi Pharma Corporation Novel amide derivatives and medicinal use thereof ugs
WO2003082828A1 (en) 2002-03-28 2003-10-09 Neurogen Corporation Substituted tetrahydroisoquinolines as c5a receptor modulators
AU2003225971A1 (en) 2002-03-28 2003-10-13 Yang Gao Substituted biaryl amides as c5a receptor modulators
JP2005530719A (ja) * 2002-03-29 2005-10-13 ニューロジェン コーポレーション 病原性炎症要素を有する状態の治療のための組み合わせ療法
US7429666B2 (en) * 2004-06-10 2008-09-30 Merck Frosst Canada Ltd. Pyridine analogs as C5a antagonists

Similar Documents

Publication Publication Date Title
JP2019524883A5 (enExample)
JP2013519675A5 (enExample)
JP2016503786A5 (enExample)
JP2009510044A5 (enExample)
JP2012515720A5 (enExample)
JP2024516371A5 (enExample)
JP2018534286A5 (enExample)
JP2010504973A5 (enExample)
JP2010500293A5 (enExample)
JP2022515293A5 (enExample)
JP2011523412A5 (enExample)
JP2010536761A5 (enExample)
JP2017522277A5 (enExample)
JP2013531013A5 (enExample)
JP2013530237A5 (enExample)
JP2013514980A5 (enExample)
JP2016534063A5 (enExample)
JP2018505192A5 (enExample)
JP2007522142A5 (enExample)
JP2008513510A5 (enExample)
JP2018168191A5 (enExample)
HRP20171511T1 (hr) Ivabradin-hidroklorid, oblik iv
JP2008543860A5 (enExample)
JP2016534133A (ja) (n,n−ジエチルカルバモイル)メチル メチル(2e)ブト−2−エン−1,4−ジオエートの結晶形態、その合成方法及び使用
JP2016529306A5 (enExample)